Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122714 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT06122714 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 95 participants.
The verdict
NCT06122714, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
Interventions
- DRUG Placebo Part A
- DRUG Placebo Part B
- DRUG AZD4144 Part A
- DRUG AZD4144 Part B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2024-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122714
The ClinicalTrials.gov registry entry for NCT06122714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Part A is the first listed.
NCT06122714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06122714 about?
NCT06122714 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants". This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
What is the current status of trial NCT06122714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2023-11-07. Estimated completion is 2024-12-04.
What interventions are being tested in trial NCT06122714?
The interventions under investigation include: Placebo Part A (DRUG), Placebo Part B (DRUG), AZD4144 Part A (DRUG), AZD4144 Part B (DRUG).
Who is sponsoring clinical trial NCT06122714?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.